Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients

被引：0
|
作者：
Yan Zhang
Jinbao Li
Jingsheng Lou
Ying Zhou
Lulong Bo
Jiali Zhu
Keming Zhu
Xiaojian Wan
Zailong Cai
Xiaoming Deng
机构：
[1] Changhai Hospital,Clinical Research Center
[2] Second Military Medical University,Department of Anesthesiology
[3] Changhai Hospital,undefined
[4] Second Military Medical University,undefined
来源：
Critical Care | / 15卷
关键词：
Septic Shock; Septic Patient; Necrotizing Fasciitis; Catalog Number; Septic Shock Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
    Zhang, Yan
    Li, Jinbao
    Lou, Jingsheng
    Zhou, Ying
    Bo, Lulong
    Zhu, Jiali
    Zhu, Keming
    Wan, Xiaojian
    Cai, Zailong
    Deng, Xiaoming
    [J]. CRITICAL CARE, 2011, 15 (01):
  • [2] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    [J]. ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [3] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [4] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    [J]. UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [5] Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
    Cheng, Xuyang
    Dai, Hehua
    Wan, Ni
    Moore, Yolonda
    Vankayalapati, Ramakrishna
    Dai, Zhenhua
    [J]. TRANSPLANTATION, 2009, 87 (12) : 1778 - 1786
  • [6] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
    Zhang, Ying
    Zhu, Weipei
    Zhang, Xueguang
    Qu, Qiuxia
    Zhang, Liyuan
    [J]. ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
  • [7] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
  • [8] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [9] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [10] Clinical Significance of Programmed Death-1 Ligand-2 in Esophageal Cancer: Comparison with Programmed Death-1 Ligand-1
    Okadome, Kazuo
    Baba, Yoshifumi
    Yagi, Taisuke
    Kiyozumi, Yuki
    Eto, Kojiro
    Hiyoshi, Yukiharu
    Ishimoto, Takatsugu
    Nagai, Yohei
    Iwagami, Shiro
    Miyamoto, Yuji
    Yoshida, Naoya
    Baba, Hideo
    [J]. CANCER SCIENCE, 2018, 109 : 414 - 414
12345